trending Market Intelligence /marketintelligence/en/news-insights/trending/tsPVlUmg9rWPMogV0b16HQ2 content esgSubNav
In This List

Report: Valeant considers selling eye surgery biz to Carl Zeiss

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Report: Valeant considers selling eye surgery biz to Carl Zeiss

Valeant Pharmaceuticals International Inc. is in discussions to sell its unit Bausch & Lomb's eye surgery products business to Germany's Carl Zeiss Meditec AG, Bloomberg News reported, citing people familiar with the matter.

The assets could be valued about $2 billion in a potential deal, the sources reportedly said.

Negotiations are ongoing, and no decisions have been made. Other bidders could also step up, according to the report.